Atopic dermatitis (AD) is a chronic skin condition marked by pruritus, inflammation, and xerosis, often linked with asthma and food allergies. Recent research reveals a significant connection between AD and obesity, with dysregulated adipokines—peptides from adipose tissue—playing a central role. Adipokines like leptin, adiponectin, resistin, and visfatin influence immune responses and inflammation, with leptin promoting Th1 and Th17 activity while adiponectin and resistin exhibit regulatory effects. Obesity appears to exacerbate AD, especially in children, through a shift toward Th17-dominant immune responses.

Targeting adipokines offers potential for novel AD therapies. Studies highlight their roles in reducing inflammation, improving skin barrier function, and alleviating AD severity. Weight management and adipokine modulation show promise in mitigating symptoms, particularly in obesity-related AD. However, the heterogeneity of AD and inconsistencies in research emphasize the need for large-scale studies to clarify the link between obesity and AD. Adipokine-targeted treatments could provide innovative solutions for patients unresponsive to conventional therapies, paving the way for precision medicine in managing this complex condition.

Reference: Zhang S, Zhang B, Liu Y, Li L. Adipokines in atopic dermatitis: the link between obesity and atopic dermatitis. Lipids Health Dis. 2024;23(1):26. doi: 10.1186/s12944-024-02009-z.